Park and Grivas Expand on Treatment Updates in Bladder Cancer

In Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a genitourinary (GU) medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, leads a discussion about treatment updates for patients with bladder cancer, including updated findings presented at the 2024 AUA Annual Meeting.

In this episode, Dr Park converses with Petros Grivas, MD, PhD, about the phase 2 SunRISe-1 trial (NCT04640623), which is a randomized, parallel-assignment, open-label clinical study evaluating the safety and efficacy of TAR-200 in combination with cetrelimab vs TAR-200 alone vs cetrelimab alone in patients with bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer with carcinoma in situ who are ineligible for or have declined radical cystectomy. Dr Grivas is a board-certified oncologist and a professor in the Clinical Research Division at Fred Hutchinson Cancer Center, the clinical director of the Genitourinary Cancers Program at the University of Washington (UW) Medicine, and an associate professor of oncology in the Department of Medicine in the Division of Hematology and Oncology at the UW School of Medicine, all in Seattle, Washington.

Drs Park and Grivas discussed the results from the SunRISe-1 trial, in addition to findings from several other trials exhibiting promise within the bladder cancer treatment field.